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 2017 WilClassical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin
hyperextensibilty, and skin fragility leading to atrophic scarring and signiﬁcant bruising. These clinical features
suggest consideration of the diagnosis which then needs to be conﬁrmed, preferably by genetic testing. The
most recent criteria for the diagnosis of EDS were devised in Villefranche in 1997 [Beighton et al. (1998); Am J
Med Genet 77:31-37].The aims set out in the Villefranche Criteria were: to enable diagnostic uniformity for
clinical and research purposes, to understand the natural history of each subtype of EDS, to informmanagement
and genetic counselling, and to identify potential areas of research. The authors recognized that the criteria
would need updating, but viewed the Villefranche nosology as a good starting point. Since 1997, there have
been major advances in the molecular understanding of classical EDS. Previous question marks over genetic
heterogeneity have been largely surpassed by evidence that abnormalities in type V collagen are the cause.
Advances inmolecular testing havemade it possible to identify the causativemutation in themajority of patients.
This has aided the further clariﬁcation of this diagnosis. The aim of this literature review is to summarize the
current knowledge and highlight areas for future research. © 2017 Wiley Periodicals, Inc.KEYWORDS: Ehlers–Danlos syndrome; classical type; cEDS; joint hypermobility; skin fragility; skin hyperextensibility
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criteria presented here represent the
consensus of the group after review of
the literature and considering the pro-
fessional experience of each of the
authors.
The committee agrees to retain the
name “classical EDS.”METHODS
Each member of the committee carried
out a literature search for classical EDS.
The results were collated. All articles
were reviewed for relevance and addi-
tional articles were identified from the
literature. The articles were summarized
and divided into themes. Themes that
were suggested by the Steering Com-
mittee of the International Consortium
on the Ehlers–Danlos syndromes were
also included to assess where there were
gaps in the literature. Each theme was
written up to include the relevant
literature in that area, focusing on
information since the Villefranche no-
sology. The original list of articles was
then reviewed to ensure all areas of the
current literature had been covered.Organ System Review
Musculoskeletal: Joint hypermobility is
present. This will be evidenced by the
presence of a Beighton score of 5 or
greater, either on examination or his-
torically. Joint instability complications
may comprise sprains, dislocation/sub-
luxation, temporomandibular joint dys-
function, pain and pes planus, dyspraxia,
and early osteoarthritis. Mild muscle
hypotonia, and some skeletal morpho-
logical alterations (scoliosis, pectus de-
formities, elbow/genus/hallux valgus)
are regularly observed. Pre-menopausal
osteopenia or an increased bone fragility
in the presence of a bonemineral density
within the range may occur [Mazziotti
et al., 2016].
Skin: The skin involvement is key
to establishing the diagnosis of classical
EDS. Skin is hyperextensible and soft,
with severe atrophic scarring and hae-
mosiderin deposition over the shins and
extensor surfaces. Easy bruising is also a
hallmark of classical EDS.Cardiovascular: While aortic root
dilation and mitral valve prolapse are
seen in classical EDS, they are rarely
clinically significant. Arterial aneurysm
and rupture have been reported in a few
individuals and families with COL5A1
mutations.
Gastrointestinal: Gastrointestinal
complaints are more commonly de-
scribed in the hypermobile type of EDS,
although they can be present in patients
with classical EDS and may include:
dysphagia, dyspepsia, reflux disease with
or without hiatal hernia, irritable-bowel
disease-like symptoms, unspecified ab-
dominal pain, defecatory dysfunctions
(constipation, diarrhea), and rectocele
[Ritelli et al., 2013; Nelson et al., 2015].
Neurologic: Pain is a common
feature of EDS. One report suggests
that pain intensity in classical EDS
patients is mild and less frequent
compared to hypermobile EDS.Literature Review
The literature was divided into 8
themes: The history of classical EDS,
the mechanism of disease, clinical
description, testing strategy, manage-
ment, differential diagnoses, genetic
counselling, and gaps/future research.THE HISTORY OF
CLASSICAL EDS
Classical EDS (OMIM #130000) is a
heritable disorder of connective tissue
characterized by skin hyperextensibility,
poor wound healing, and joint hyper-
mobility. Classical EDSwas first noted to
be a distinct type of EDS in the 1960s
when Beighton reviewed 100 patients
and described a patient with distinct
features which he termed EDS gravis
[Beighton, 1968]. Patients were noted to
have characteristic findings on electron
microscopy, which helped to differenti-
ate between EDS diagnoses [Vogel et al.,
1979]. In 1988, gravis type was termed
EDS type I and themilder, mitis typewas
labelled EDS type II [Beighton et al.,
1988]. Type V collagen was implicated
after mouse models with mutations in
COL5A2 showed features of the condi-
tion [Andrikopoulos et al., 1995]. Thiswas shortly followedby the first reports of
COL5A1 mutations in patients with
classical EDS [Nicholls et al., 1996;
Wenstrup et al., 1996; De Paepe et al.,
1997]. Linkage to COL5A1 also sug-
gested the EDS types I and II were
phenotypic variation of the same condi-
tion [Burrows et al., 1996]. In 1996, a
balanced translocation interrupting the
COL5A1 gene was identified and hap-
loinsufficiency was suggested as the cause
of the patient’s EDS phenotype [Toriello
et al., 1996]. The name classical EDSwas
given when the Villefranche nosology
was written in 1997 [Beighton et al.,
1998]. Initially other genes were thought
to be involved, as COL5A1 and
COL5A2 mutations were only found
to account for around half of classical
EDS patients [Schwarze et al., 2000;
Malfait et al., 2005]. Advances in
molecular testing have allowed more
type V collagen abnormalities to be
identified, and recent reports indicate
that the majority of patients with classical
EDS do have a mutation in either
COL5A1 or COL5A2 [Symoens et al.,
2012; Ritelli et al., 2013].Classical EDS (OMIM
#130000) is a heritable
disorder of connective tissue
characterized by skin
hyperextensibility, poor
wound healing and joint
hypermobility. Classical EDS
was first noted to be a distinct
type of EDS in the 1960s
when Beighton reviewed 100
patients and described a
patient with distinct features
which he termed EDS gravis.THE MECHANISM OF
DISEASE
Reduction in the amount of type V
collagen is central to the pathogenesis of
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Paepe and Malfait, 2012]. Type V
collagen has a regulatory function in
fibrillogenesis. The phenotype is caused
by disturbance in the regulatory func-
tion of type V collagen [Symoens et al.,
2012].
Type V collagen is a fibrillar
collagen present in small amounts in a
wide variety of tissues [Malfait and De
Paepe, 2005]. It is mainly found in
vertebrate tissues as the heterotrimer a1
(V)2a2(V) [Viglio et al., 2008]. Type V
collagen and type I collagen come
together to form collagen fibrils.
COL5A1 haploinsufficiency is, there-
fore, a limiting factor for an adequate
production of heterotrimers, hence
compromising the regulatory role in
fibrils assembly. Most of the a1(V)2a2
(V) heterotrimer is embedded within
the fibril, apart from the amino-terminal
propeptide domain which remains ex-
posed on the surface and has a role in
fibril assembly and regulating fibril
diameter [Birk, 2001].
TheCOL5A1 gene encodes the a1
chain and is located at 9q34.2-q34.3.
The COL5A2 gene encodes the a2
chain and is located at 2q31. Both genes
are large, comprising 66 and 52 exons,
respectively. The majority of patients
have mutations inCOL5A1. A report of
93 gene positive patients found 73 had
COL5A1 mutations, 13 had COL5A2
mutations, and in 7 cases the mutation
could not be identified; however,COL5
null allele testing confirmed the abnor-
mality was in type V collagen [Symoens
et al., 2012]. In this series two thirds of
the mutations were found to be de novo.
A series of 40 patients achieved a
mutation detection rate of 93% [Ritelli
et al., 2013]. Both studies confirmed
that COL5A1 and COL5A2 are the
major, if not the only genes involved.
The most common molecular de-
fects result in nonsense mediated decay
of the mutated COL5A1 mRNA
[Schwarze et al., 2000]. Whilst hap-
loinsufficiency is seen most often,
dominant-negative mutations are also
reported [Wenstrup et al., 2000]. In
general genotype–phenotype correla-
tions are not found, but there are a
couple of possible exceptions.Mutations in the highly conserved
amino-terminal propeptide domain of
a1(V) that cause atypical splicing out-
comes have been associated with a more
severe classical EDS phenotype with
kyphoscoliosis and retinal detachment
[Symoens et al., 2011]. There is one
report that questions whether mutations
involving glycine substitutions near the
C-terminal end cause an increased
arterial risk [Monroe et al., 2015].
Although numbers are still limited,
COL5A2 gene mutations are thought
to result in a phenotype at the more
severe end of classical EDS spectrum
[Symoens et al., 2012].CLINICAL DESCRIPTION
The Villefranche criteria list three major
criteria for classical EDS [Beighton
et al., 1998]:(1) Skin hyperextensibility
(2) Widened atrophic scars (manifestation
of tissue fragility)
(3) Joint hypermobilityIn addition, there are a number of
minor criteria which show less diagnos-
tic specificity:(1) Smooth velvety skin
(2) Molluscoid pseudotumours
(3) Subcutaneous spheroids/spherules
(4) Complications of joint hypermobility
(e.g., sprains, dislocations/subluxa-
tions, pes planus)(5) Muscle hypotonia, delayed gross mo-
tor development(6) Easy bruising
(7) Manifestations of tissue extensibility
and fragility (e.g., hiatus hernia, anal
prolapse in childhood, cervical
insufficiency)(8) Surgical complications (postoperative
hernias)(9) Positive family historyThe Villefranche criteria are still
considered relevant for classical EDS.
A study of 126 suspected classical EDS
patients found that 93 out of the 102 that
demonstrated all three major Ville-
franche criteria for classical EDS were
found to have a type V collagenabnormality [Symoens et al., 2012].
They suggested making the diagnostic
criteria more stringent as fulfilling all
three major criteria was seen to be a
reliable indicator of a type V collagen
mutation. Another review of 40 patients
also found that these three major criteria
are considered to still be useful for
clinical diagnoses in the majority of
patients [Ritelli et al., 2013].A study of 126 suspected
classical EDS patients found
that 93 out of the 102 that
demonstrated all three major
Villefranche criteria for
classical EDS were found to
have a type V collagen
abnormality.There have been a number of
typical case histories of classical EDS
described. These suggest that investiga-
tions into childhood bruising are often
the first presentation to medical pro-
fessionals, and if skin hyperextensibility
and joint hypermobility are noted at this
time, the diagnosis is generally made [De
Paepe and Malfait, 2012; Byers, 2013;
Morais et al., 2013; Sobey, 2014].
Bruising is generally a feature seen
when children start to crawl and walk,
with the characteristic scarring becom-
ing apparent after knocks and bumps
around the same time. Hypermobility
may delay motor development, but
intellectual development is unaffected.Skin Features
Skin hyperextensibility has been shown
to be a reliable and reproducible feature
of classical EDS [Remvig et al., 2010].
This group confirmed that patients with
classical EDS show extensibility beyond
the normal range (Fig. 1). However,
they found skin consistency to be an
unreliable test and concluded that skin
consistency should not be included in
the diagnostic criteria for classical EDS.
Figure 1. Hyperextensible skin in Classical Ehlers-Danlos Syndrome.
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hyperextensibility to be a good indicator
for classical EDS, as it quite specific to
this diagnosis [Heidbreder et al., 2008;
Catala-Petavy et al., 2009] Skin fragility
with atrophic scarring and poor wound
healing is a hallmark of the classical type
of EDS [Beighton et al., 1998] (Fig. 2).Cardiovascular Involvement
Nine patients (three in one family) have
been reported to have molecularly
confirmed classical EDS and vascular
events [Monroe et al., 2015]. To deter-
mine whether there is any reporting bias
it is helpful to compare these cases to the
larger patient series that have been
reported. Twenty-five patients with
proven type V collagen abnormalities
showed no vascular events at the time of
writing [Malfait et al., 2005]. A series of
102 patients, 93 with collagen type V
abnormalities, had two patients with
vascular complications which included
aneurysm and dissection of medium
sized artery [Symoens et al., 2012]. They
reported that severe or progressive
cardiac-valvular disease was absent in
their cohort. A report of 40 patients
showed no patients with type V collagen
abnormalities that had severe cardiovas-
cular involvement [Ritelli et al., 2013].
The family of three are two brothers
and their mother who were given a
clinical diagnosis of vascular EDS
[Monroe et al., 2015]. One brother
died age 43 due to a subarachnoid bleed,
after previously having a ruptured left
subclavian artery age 15 years and a
coeliac artery aneurysmwas resected age
18 years with significant bleeding. His
mother had died at age 28 while under
anaesthesia for dental extraction; the
post mortem revealed a renal artery tear.
The other brother died age 34 following
a right iliac artery rupture; his tissues
were compared to rice paper in the
operating theatre. They were all shown
to have a COL5A1 p.(Gly1537Val)
mutation. This family represents the
only report of familial vascular events
with a COL5A1mutation. The authors
wondered about modifying genes in the
family or whether there could be a
genotype–phenotype correlation. Theyspeculated there could be increased
arterial risk in cases involving glycine
substitutions near the C-terminal end.
Another report of a patient with a
glycine substitution at theC-terminal end
of the triple helix domain had a symp-
tomatic superior mesenteric artery aneu-
rysm age at 9 years [de Leeuwet al., 2012].
This patient was said to fit clinically with a
classical EDS diagnosis and was found to
have a COL5A1 p.(Gly1564Asp) muta-
tion. Two further vascular events have
been reported at young ages.One report is
of a 13-year-old girl with classical EDS
who had a superior mesenteric artery
rupture andwas found to have aCOL5A1
missense mutation c.1532G>T
p.(Gly511Val) [Yasuda et al., 2013].
Another patient with a COL5A1 p.
(Gly922Asp) mutation was diagnosed
with classical EDS at 4 years of age and
presented at age 11 with a superior
mesenteric artery aneurysm with throm-
bosis [Karaa and Stoler, 2013]. This
patient was treated with anticoagulation,
and a week later he ruptured his inferior
mesenteric artery.
Two patients with classical EDS and
hypertension have been reported follow-
ing vascular events. A patient with a
COL5A1 mutation c.3184C>T p.
(Arg1062) who already had a clinical
diagnosis of classical EDSwent on tohave
a left common iliac artery rupture at age
42 years [Borck et al., 2010]. This patient
had been diagnosed with hypertension at
40 and treated with clonidine, metopro-
lol and valsartan/hypochlorothiazide.
The authors felt they could not exclude
a chance association between the classical
EDS diagnosis and the rupture, but felt a
causal relationship was more likely. They
considered whether the concurrent hy-
pertension might have played a part,
causing a second hit. However, their
view was that a systematic counselling of
the risk of arterial rupture in classical
EDS should await confirmation of this
association in larger series. Another
patient with chronic hypertension
(although well controlled) with a
COL5A1 nonsense mutation
c2185C>T p.(Gln729) had an iliac
artery dissectionwhilst resistance training
[Mehta et al., 2012]. This time the
authors considered a triple hit effect;chronic hypertension, elevated vascular
stress from resistance training, and his
underlying weakened collagen matrix
due to classical EDS. They suggested
avoiding intense resistance training and/
or tighter control of blood pressure.
Aortic root dilation has been re-
ported in classical EDS [Wenstrup et al.,
2002; McDonnell et al., 2006; Atzinger
et al., 2011]. It appears to be more
common in young patients and rarely
progresses [Atzinger et al., 2011]. Mitral
valve prolapse can occur in up to 6% of
cases but tends to be of little clinical
significance [Atzinger et al., 2011].
Newly recognized features
Features not mentioned in the Ville-
franche criteria that arise in the literature
include premature rupture of fetal
membranes, characteristic facial fea-
tures, absence of striae, scoliosis, cardiac
and blood vessel fragility. Premature
rupture of fetal membranes can result in
prematurity and this was reported to
affect half of classical EDS patients, but is
now thought not to be so common
[Wenstrup et al., 2000]. The character-
istic facial features described are; epi-
canthic folds, excess skin on eyelids, a
prematurely aged appearance, and scars
on the forehead and chin [Malfait and
De Paepe, 2005]. Absence of striae has
been noted in classical EDS patients
[Sobey, 2014], although some patients
with confirmed classical EDS have been
seen to have striae. Three patients out of
40 were reported to have striae in one
study [Ritelli et al., 2013]. Dual-energy
X-ray absorptiometry (DXA) and quan-
titative vertebral morphometry were
performed in 12 unrelated adult patients
with classical EDS which showed bone
mineral density below the expected
range for age (osteopenia) in about
33.3% of patients and pre-menopausal
osteoporosis in one patient. Giant
bladder diverticula have been described
in four cases, all male [Burrows et al.,
1998]. In two reports the subtype of
EDS was not given but the descriptions
were compatible with classical EDS.
Gastrointestinal findings
Gastrointestinal (GI) manifestations
were analyzed among a cohort of 73
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EDS. The most common upper GI
symptoms were nausea (46.5%), vomit-
ing (30.2%), and gastroesophageal reflux
(30.2%); the most common lower GI
symptom was chronic constipation
(37.2%) [Nelson et al., 2015]. Gastro-
esophageal reflux and defecatory dys-
functions (i.e., chronic constipation)
were also described in the cohort of
39 classical EDS patients reported in
Ritelli et al. [2013].
Oral findings
Overall periodontal status in EDS is
poor. One case of abnormal pulp shape
and seven with pulp calcification were
seen out of nine classical EDS patients
examined [De Coster et al., 2005a]. It
has been suggested that the absence of
the inferior labial and lingual frenulae is
a helpful marker for hypermobile and
classical EDS, but the total numbers of
classical EDS patients reported to date
are too small to conclude that this is
useful sign in this subtype [De Felice
et al., 2001]. Pierro et al. [2006] reported
on ligneous periodontitis in Ehlers-
Danlos syndrome. Temporomandibular
joint dysfunction is a common feature
and a frequent cause of secondary
headache in classical EDS patients with
generalized joint laxity [De Coster et al.,
2005b].
Ocular findings
Macro- and microstructural changes of
the cornea were found in classical EDS
patients [Villani et al., 2013]. Classical
EDS patients have been shown to have
thin, steep and transparent corneas as
well as floppy eyelids [Segev et al.,
2006; Villani et al., 2013]. Both studies
found that these changes did not cause
an increase in refractory errors (includ-
ing astigmatism) nor an increase in
keratoconus. This supports the lack of
correlation between corneal thickness
and refractive error. Villani et al.
[2013] also found that the patients
reported no complaints of ocular
surface symptoms, despite having ab-
normal ocular surface symptoms and
reduced tear secretion when compared
to controls. One caveat concerning the
report by Villani et al. [2013] is that thediagnosis of classical EDS was not
supported by molecular testing in the
reported population.
Pain and Neurological Features
Pain is considered a common feature in
EDS patients, but it has been shown to
be more prevalent and more severe in
patients with hypermobile EDS than in
those with classical or vascular EDS
[Voermans et al., 2010]. The authors
correlate pain intensity with the degree
of joint hypermobility, dislocations, and
previous surgery. A decrease in quality of
life has been reported but found not to
be significantly different between classi-
cal and hypermobile patients, provided
they have been diagnosed and are under
multidisciplinary management [Castori
et al., 2010]. When compared to
patients with vascular EDS and patients
with homozygous and heterozygous
TNXB mutations, the patients with
classical EDS reported the most neuro-
muscular complaints [Voermans et al.,
2009]. This study found mild, moderate
or severe muscle weakness on examina-
tion of all of 10 classical EDS patients.
They suggest that the neuromuscular
involvement is due to the abnormal
extracellular matrix within muscle and
peripheral nerve. This is an alternative
explanation to the view that it is exercise
avoidance, for fear of dislocations and
sprains, which leads to muscle weakness
and fatigue. Rowe et al. [1999] reported
an association between orthostatic in-
tolerance, chronic fatigue, and Ehlers-
Danlos syndrome. Autonomic burden
has been reported to be lower in classical
EDS than in hypermobile EDS, and
classical EDS patients had levels more
comparable to those reported by vascu-
lar EDS patients [De Wandele et al.,
2014].TESTING STRATEGY
The diagnosis of classical EDS can be
confirmed by identifying the pathogenic
causative mutation in COL5A1 or
COL5A2. As the number of identifiable
mutations has increased, molecular test-
ing has been the main route for classical
EDS testing. Testing strategies generally
start with COL5A1 sequencing. IfCOL5A1 is negative, sequence
COL5A2 and proceed to Multiplex
Ligation-dependent Probe Amplifica-
tion (MLPA) for COL5A1 [De Paepe
andMalfait, 2012; Ritelli et al., 2013]. If
the causative mutation is not identified,
COL1A1 sequencing should be consid-
ered, at least in a subset of patients with
vascular and/or valvular involvement,
or history thereof [Ritelli et al., 2013;
Colombi et al., 2016] (see also “Ehlers–
Danlos Syndromes, Rare Subtypes” by
Brady et al., this issue).The diagnosis of classical
EDS can be confirmed by
identifying the pathogenic
causative mutation in
COL5A1 or COL5A2. As
the number of identifiable
mutations has increased,
molecular testing has been the
main route for classical EDS
testing. Testing strategies
generally start with COL5A1
sequencing.Molecular investigations identify
mutations in the majority, but currently
not all, patients with the diagnosis
[Symoens et al., 2012]. Pathogenicity
must be determined and there is a
registry of reported collagen gene
variants [Dalgleish, 1998].
The pathogenicity of one reported
variant remains unclear. The
p.(Gly530Ser) variant in COL5A1 is
reported to be potentially disease modi-
fying in the heterozygous state and
disease causing in the homozygous state
[Giunta and Steinmann, 2000; Giunta
et al., 2002]. However, there is still some
uncertainty about whether this variant is
disease causing, due to its frequency in
the general population and the fact that
not all molecular causes of classical EDS
can currently be identified. Another
study found the frequency of the
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patients with classical EDS, vascular
EDS, osteogenesis imperfecta (OI),
and the three control groups they used
as comparison [Mitchell et al., 2009].
They state that if homozygosity of this
variant did cause classical EDS, 1 in 400
people would be affected. This is much
higher than the current suspected
frequency of classical EDS. Hence,
they consider homozygosity of this
variant is unlikely to cause classical EDS.
When a pathogenic mutation can-
not be found, type V collagen abnormal-
ity can be sometimes be demonstrated by
the COL5A1 null allele test [Greenspan
and Pasquinelli, 1994; Schwarze et al.,
2000;Mitchell et al., 2009;DePaepe and
Malfait, 2012; Symoens et al., 2012]. The
patient must be heterozygous for a
polymorphic marker in COL5A1
gDNA. cDNA from a skin biopsy is
then tested to look for the presence of
one or both markers. If a marker is not
expressed that allele is assumed not to be
functional, that is, “null” [Malfait andDe
Paepe, 2005].
Typical frequent collagen flowers on
electron microscopy (EM) of skin can be
a helpful diagnostic tool for classical EDS,
however collagen flowers are not unique
to this condition. Electronmicroscopyof
a skin biopsy can be used to direct testing
[Sobey, 2015], and electron microscopy
can aid diagnosis [Vogel et al., 1979;
Hausser and Anton-Lamprecht, 1994].
The absence of typical collagen flowers
would go against the diagnosis, as there
are no reports of patients with type V
collagen abnormalities without collagen
flowers on EM [de Moraes et al., 2000;
Proske et al., 2006; Symoens et al., 2012].
However, collagen flowers are not
specific to classical EDS and have been
reported in other connective tissue
disorders including OI and Ullrich
congenital muscular dystrophy
(UCMD) [Kirschner et al., 2005;
Hermanns-Le^ and Pierard, 2007;
Balasubramanian et al., 2015].
Collagen flowers on EM should be an
indicator to look for COL1A1 muta-
tions, when clinical features of classical
EDS are present in the absence of a
COL5 abnormality.Collagen protein analysis of cultured
fibroblasts is not an effective diagnostic
tool for classical EDS as typeV collagen is
only synthesized at low levels [Malfait
et al., 2010]. This analysis may be used to
exclude alternative diagnoses in the
absence of genetic confirmation and
may be helpful for the confirmation of
themutation effect, that is, recognitionof
splice site mutations.MANAGEMENT
The key management advice is fairly
consistent and focuses on the skin and
joints [Steinmann et al., 2002;Proske et al.,
2006; Malfait et al., 2010; Sobey, 2014].
The advice on managing the skin is
to:
Avoid undue trauma. Children are
particularly prone to injury and benefit
from protective pads and bandages.
Custom made shin pads can be
obtained from local appliance depart-
ments. Contact sports should be
avoided.
Wounds should be expertly closed
via sutures without tension. Patients
should be known to their local plastic
surgeons to enable access in emergencies.
Stitches should be applied generously, in
layers and left in place twice as long as
usual. Tape can also help prevent stretch-
ing of the scar, but needs careful removal.Wounds should be expertly
closed via sutures without
tension. Patients should be
known to their local plastic
surgeons to enable access in
emergencies. Stitches should
be applied generously, in
layers and left in place twice
as long as usual. Tape can
also help prevent stretching of
the scar, but needs careful
removal.Ascorbic acid (2 g/day for adults)
may reduce bruising, but does not affect
the basic clinical picture.
Surgery may be difficult due to
tissue fragility and original problem may
reoccur, for example, hernia.
Deamino-Delta-D-Arginine Vaso-
pressin (DDAVP) may be useful to
normalize bleeding time. Although
bleeding is related to tissue and capillary
fragility rather than clotting time, it may
be beneficial in case of bruising, epistaxis
or before procedures such as dental
extractions.
Avoid excessive sun exposure to
reduce the risk of premature skin aging.
Plastic surgery to remove mollus-
coid pseudotumors may be considered
in presence of psychological/aesthetic
issues.
The musculoskeletal management
advice is:
Physiotherapy is beneficial for chil-
dren with hypotonia and delayed motor
development.
Light, non-weightbearing, muscle
strengthening exercise such as isometric
training and swimming are beneficial for
hypermobile joints and pain
management.
Competitive activities, such as
gymnastics, repetitive heavy lifting,
and sports that cause heavy joint stress,
are not advisable. Mild strength training
has shown benefit in joint stabilization
and hypotonia.
Avoid “showing off” hypermobil-
ity and excessive stretching of the
hypermobile joints.
Joint hypermobility is best managed
by Rheumatology, Physiatry and Sports
Medicine, together with physiotherapy,
proprioception exercises, and occupa-
tional therapy (OT).
Ring splints, carefully considered
bracing, and orthotics may be beneficial.
Skin fragility,muscle hypotonia, joint
instability, and pain are key aspects of the
condition and should be recognized and
discussed with the patient. Lifestyle and
professional choices may need to be
adapted.
There are several articles giving
contradictory advice on resistance
exercise. One report found heavy
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safe, although their numbers were small
they saw an improvement in muscu-
lotendinous function and a reduction
in fatigue [Møller et al., 2014].
Another report describes a case of iliac
artery dissection following vigorous
physical exercise [Mehta et al., 2012].
Schroeder and Lavallee [2006] offer
guidance for athletes with EDS of all
types.
The advice on pain management
includes:
Anti-inflammatory drugs and pain
medications using narcotics only as a
very last resort.
Neurological assessment in patients
with symptoms suggestive of neuro-
pathic pain/compression neuropathy.
Regular, light, non-weightbearing
exercise.
Relaxation techniques including
mindfulness-based stress reduction and
biofeedback.
Counselling support including cog-
nitive behavioral therapy. See also “Pain
Management in Ehlers-Danlos Syn-
drome” by Chopra et al., this issue.Cardiac Management
Cardiac assessment including echo-
cardiography to look for aortic root
dilation and mitral valve prolapse.
Mitral valve prolapse may need man-
agement. Aortic root size and mitral
valve prolapse are increased in pa-
tients with classical EDS, but they
tend to be of little clinical signifi-
cance. Echocardiography may be
warranted, but in symptom-free
adults frequency can be reduced
[Atzinger et al., 2011]. If this is
normal in adulthood no follow up is
required [Malfait et al., 2010].
Consider vascular imaging/use of
blood pressure medication if the patient
has a glycine substitution identified near
the C-terminal end of the triple helix, or
on the basis of their family history
[Monroe et al., 2015].Gastrointestinal Management
Endoscopy and colonoscopy should be
performed with care due to a possiblyincreased risk of mucosal bleeding and
tissue fragility.Pregnancy Management
Follow up throughout pregnancy is
warranted.
Preterm delivery is more likely when
the fetus is affected and is mainly due to
premature rupture of the membranes.
Breech presentation is more com-
mon if the baby is affected.
After delivery, extension of episiot-
omy incisions and pelvic prolapse
leading to urinary/faecal incontinence
may occur due to tissue fragility and
extensibility. Treatment of symptomatic
pelvic prolapse remains problematic in
classical EDS.DIFFERENTIAL DIAGNOSIS
There are a large number of con-
ditions reported to be amongst the
differentials when a diagnosis of
classical EDS is being considered.
One paper specifically on classical
EDS gives a detailed description of
18 differential diagnoses [Malfait et al.,
2010]. Another highlights the need to
distinguish hyperelastic skin from the
redundant skin seen in cutis laxa
syndromes and Menkes disease
[Malfait and De Paepe, 2005].
A paper describing the differential
diagnoses for connective tissue diseases
in general, mentions features similar to
those of classical EDS in four other
conditions [Murphy-Ryan et al., 2010]:(1) Cardiac-valvular EDS—In this condi-
tion, patients sometimes present with
the skin and joints of classical EDS but
have an increased risk of cardiac
valvular complications and autosomal
recessive inheritance (see also
“Ehlers–Danlos Syndromes,Rare Sub-
types” by Brady et al., this issue).(2) Classical-like EDS due to complete
tenascin X deficiency—can present
with a phenotype similar to classical
EDS but without the typical scarring,
and with autosomal recessive inheri-
tance (see also “Ehlers–Danlos Syn-
dromes, Rare Subtypes” by Brady
et al., this issue).(3) Spondylodysplastic EDS due to
SLC39A13 mutations—a rare reces-
sive condition caused by mutations in
SLC39A13, which presents with
atrophic scarring similar to that seen
in classical EDS, in addition to fragile
skin which appears prematurely aged
on hands and feet. Muscle
atrophy, pes plans, postnatal growth
deficiency, and small joint
contractures are also characteristic
[Giunta et al., 2008] (see also
“Ehlers–Danlos Syndromes, Rare
Subtypes” by Brady et al., this issue).(4) Loeys–Dietz syndrome—which can
present with a whole spectrum of
features including the translucent and
velvety skin and joint laxity seen in
classical EDS, but also craniofacial
features and vascular tortuosity not
typical of cEDS.
A review on the differential diag-
noses of joint hypermobility syndrome
(JHS)/EDS hypermobile type (hEDS)
includes classical EDS [Colombi et al.,
2015]. In a small number of cases,
patients with classical EDS and those
with JHS/hEDS can present similarly. In
one study, two adult patients with
confirmed classical EDS were reported
to have no atrophic scars [Ritelli et al.,
2013]. Another study reported hEDS
patients with hyperextensible skin
[Castori et al., 2015].
Also to be included in the differen-
tial diagnosis of classical EDS is the
dermatosporatic type of EDS, which is
an autosomal recessive disorder charac-
terized by extreme skin fragility with
congenital or post-natal skin tears.
Typically the skin is redundant, with
excessive palmar wrinkling and severe
bruisability with a risk of subcutaneous
hematomas and haemorrhage Postnatal
growth retardation with short limbs,
hand and feet, which are not typically
features of cEDS, are seen in the
dermatosporatic type (see also
“Ehlers–Danlos Syndromes, Rare Sub-
types” by Brady et al., this issue).
A review of case reports and patient
series reveals a number of incidences
where a clinical diagnosis of classical EDS
was altered after genetic testing identified
an alternative diagnosis. In all cases, they
all involved mutations in type I collagen.
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forms of type I collagen abnormality
that can present with EDS features:(1) Cardiac valvular EDS—an autosomal
recessive condition caused by total
absence of a2(1) collagen chain [De
Paepe and Malfait, 2012]. The condi-
tion was named because three patients
were reported to have aortic or mitral
valve requiring replacement surgery in
adulthood [Schwarze et al., 2004]. A
review of all reported cases concludes
that loss of function mutations result in
a phenotype similar to hEDS or
classical EDS but with cardiac valve
disease in adulthood while gain of
function mutations lead to a severe OI
phenotype [Malfait et al., 2006] (see
also “Ehlers–Danlos Syndromes, Rare
Subtypes” by Brady et al., this issue).(2) “Classic EDS-like with a propensity
for arterial rupture”/“vascular-like
classical EDS” are two names that
have been used for the condition
caused by COL1A1 mutations involv-
ing substitutions of arginine for cyste-
ine. This condition can present as
classical EDS with an increased risk for
arterial dissection [Malfait et al., 2007;
Ritelli et al., 2013; Gaines et al., 2015].
Three patients were described who
had arginine to cysteine substitutions
in the pro-alpha (l) collagen chain and
one had presented as classical EDS
[Malfait et al., 2007]. They suggest
that this shows the need to differentiate
COL1 patients (given the phenotypic
similarity) as there is vessel fragility in
patients with COL1A1 arginine to
cysteine mutations. The molecular
characterization of 40 patients with
classical EDS showed that one patient
had a COL1A1 p.(Arg312Cys) muta-
tion [Ritelli et al., 2013]. This patient
was reported to be similar to the other
classical EDS patients except that he
had vascular involvement (see also
“Ehlers–Danlos Syndromes, Rare
Subtypes” by Brady et al., this issue).(3) OI/EDS overlap syndrome.Patients with mutations at the
N-terminal end of both COL1A1 and
COL1A2, which are seen to affect the
processing of the N-propeptide, canpresent phenotypically as EDS rather
than OI [Malfait et al., 2013]. This is in
contrast to patients with mutations in the
same regionwhodonot showdelayed type
I procollagen N-propeptide processing on
SDS–PAGE analysis, who present with an
OI phenotype. The potential risk for
vascular rupture associated with these
mutationsmeans theyneed tobediagnosed
correctly, particularly given the clinical
overlap. This again highlights the need to
consider type I collagen in patients
presentingwith EDS features. The authors
recognized that the further work was
needed to fully characterize this pheno-
type, but suggest being aware of the
potential for vascular aneurysm or rupture
at ayoungage and recommendcautionand
consideration of the riskof vascular fragility
in event of surgical or other invasive
procedures.GENETIC COUNSELING
Classical EDS is inherited in an
autosomal dominant pattern. Affected
individuals have a 50% chance of
passing on the condition in each
pregnancy. For siblings of an affected
person it will depend on whether one
of the patents is also affected. If a parent
is affected the other children will have a
50% chance of being affected. Intra-
familial variability has been reported
[Burrows et al., 1996]. About 50% of
cases are thought to be de novo
[Malfait et al., 2010]. If the parents
are unaffected there is a theoretical risk
to the other children due to gonadal
mosaicism, however, this has not yet
been reported [Malfait et al., 2010].
Once the molecular cause is known
for a patient, cascade testing is possible to
confirm or exclude the diagnosis in
relativeswhomayhave amilder phenotype
[Ritelli et al., 2013]. Prenatal testing and
preimplantation genetic diagnosis are pos-
sible once the mutation is known; how-
ever, requests for these are not common for
conditions that do not affect intellect or life
span [Malfait et al., 2010].Diagnostic Criteria
After review of the literature, and
considering the clinical experience ofthe authors, we recommend the follow-
ing diagnostic criteria:
Major criteria(1) Significant skin hyperextensibility and
atrophic scarring.(2) Generalized joint hypermobility.Minor criteria(1) Easy bruising.
(2) Soft, doughy skin.
(3) Skin fragility (or traumatic splitting).
(4) Molluscoid pseudotumours.
(5) Subcutaneous spheroids.
(6) Hernia (or history thereof).
(7) Epicanthal folds.
(8) Complications of joint hypermobility
(e.g., sprains, dislocation/subluxation,
pain, pes planus).(9) Family history of a first degree relative
who meets clinical criteria.Minimal criteria suggestive for a diagnosis
of classical EDS
Major criteria (1)—Skin hyperextensi-
bility and atrophic scarring
Plus
Either: Major criteria (2)—generalized
joint hypermobility
Or: three of the nine minor criteria
Comments
Skin is hyperextensible if it can be
stretched over a standardized cut off in
the following areas: 1.5 cm for the distal
part of the forearms and the dorsum of
the hands; 3 cm for neck, elbow and
knees; 1 cm on the volar surface of the
hand (palm).
Abnormal scarring can range in
severity. Most patients have extensive
atrophic scars at a number of sites. A
minority of patients are more mildly
affected. The relevance of surgical scars
should be considered with caution in
classical EDS, they can appear normal in
patients with classical EDS if well man-
aged. Atrophic surgical scars can be found
in the general population due to mechan-
ical factors and site of the incision.
Joint hypermobility (JHM) is eval-
uated according to the Beighton score; a
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positive for the presence of generalized
joint hypermobility. Since joint hyper-
mobility decreases with age, patients
with a Beighton score <5/9 may be
considered positive based on their
historical observations.
Easy bruising can occur anywhere
on the body, including unusual sites.
The pretibial area often remains stained
with hemosiderin from previous bruises.
Subjective abnormality of the skin
texture is appreciable by touching the skin.
Molluscoid pseudotumors are fleshy
lesions associated with scars, found over
pressure points (e.g., elbow, fingers).
Subcutaneous spheroids are small
spherical hard bodies, frequently mobile
and palpable, on the forearms and shins.
Spheroids may be calcified and detect-
able radiologically.
Epicanthal folds are often seen in
childhood but may also be seen in adults.
Verification of clinical diagnosis
Confirmatory analysis is recommended
for any patient meeting the above
clinical criteria.
Molecular analysis of COL5A1 and
COL5A2 genes identifies a causal muta-
tion in more than 90% of the patients
[Symoens et al., 2012;Ritelli et al., 2013].
Molecular screening by means of targeted
resequencing of a gene panel that includes
at least the COL5A1, COL5A2, and
COL1A1 gene, or by WES or WGS is
indicated. When no mutation is identi-
fied, this approach should be comple-
mented with a copy number variant
(CNV) detection strategy to identify large
deletions or duplications.
If genetic testing is not available,
electron microscopy findings of collagen
flowers on skin biopsy can support the
clinical diagnosis.
Absence of these confirmatory
findings does not exclude the diagnosis;
however, alternative diagnoses should
be considered in the absence of a type V
collagen gene mutation or electron
microscopy findings.GAPS/FUTURE RESEARCH
A study of the management of vascular
complications in EDS described 15patients with clinical diagnoses of classi-
cal EDS with two having thoracic aortic
aneurysm repair and two having ab-
dominal aortic aneurysm repair [Brooke
et al., 2010]. The authors recognized
that they were limited by reliance on
clinical criteria for diagnosis when
biochemical and genetic testing is
more accurate. The evidence that
COL1 mutations have an increased
vascular risk raises this particular ques-
tion for these patients. This highlights
the benefit of molecular confirmation of
patients for research purposes.
A large proportion of the current
literature on patients that have had
molecular testing focuses on con-
firming the diagnosis, while the
literature on clinical features and
management is often not based on
molecularly characterized popula-
tions. Further studies of associated
features in confirmed classical EDS
patients is warranted. There are some
recent large patient reviews that have
helped to develop the understanding
of classical EDS. There is huge
potential for research using these
large patient groups with molecularly
confirmed diagnoses.
Mutations in COL5A2 account for
a relatively small number of cases. As
more mutation analysis is carried out,
genotype-phenotype correlations may
become more apparent.
Large scale studies on vascular risk
and cardiac features would aid manage-
ment. A few cases studies may be
skewing the data and further clarifica-
tion of this would be helpful for patients
with type V collagen mutations. How-
ever, it is clear that in the absence of
molecular testing, the potential for a
type I collagen mutation with an
increased risk of arterial rupture cannot
be ruled out.
Another question that would ben-
efit from further research is whether a
lack of striae can be used as a good
indicator for classical EDS and help to
direct molecular testing.
Literature is lacking on the fre-
quency of dysautonomia, chronic fatigue
syndrome, gastrointestinal involvement,
Chiari and cranio-cervical instability in
this patient population.Pregnancy and delivery in classical
EDS is another area that would benefit
from clear management guidelines.
More data are needed in regard to
mild, persistent strength training in
relation to the treatment of the hypoto-
nia seen in some cases of classical EDS.
The role of fitness, exercise, and
rehabilitation in the functional ability
and quality of life measure in those with
classical EDS is an area for further
investigation.
Finally, there is a lack of good
prevalence and natural history data for
classical EDS.SUMMARY
A diagnosis of classical EDS is indicated
by the well-described triad of hyper-
extensible skin, atrophic scarring, and
hypermobile joints. Although a set of
clinical criteria has predominated diag-
nosis, other conditions do present
similarly. Confirmation of diagnosis
informs management and is vital for
research purposes. Much of the early
literature on classical EDS is limited by
the lack of laboratory confirmation of
diagnoses.
The diagnosis of classical EDS can
be confirmed by identifying the path-
ogenic causative mutation in COL5A1
or COL5A2. Molecular investigations
identify mutations in the majority, but
currently not all patients with a clinical
picture compatible with the diagnosis.
Where genetic confirmation has not
been possible, a type V collagen
abnormality can sometimes be demon-
strated by the COL5A1 null allele test.
Typical frequent collagen flowers on
electron microscopy (EM) of skin can
be a helpful diagnostic tool for classical
EDS, however, collagen flowers are not
unique to this condition. Collagen
flowers on EM should be an indicator
to test COL1A1 and COL1A2 when
clinical features of classical EDS are
present in the absence of a COL5
abnormality. Patients with a type 1
collagen abnormality can present with
a similar initial clinical appearance to
classical EDS, but they have a higher
risk of vascular events and need
appropriate management.
RESEARCH REVIEW AMERICAN JOURNAL OF MEDICAL GENETICS PART C (SEMINARS IN MEDICAL GENETICS) 37The management advice for classi-
cal EDS has remained consistent over a
number of years. There are now a large
number of patients with molecularly
confirmed classical EDS and these
provide a basis for further research on
management. Further evidence on car-
diac risks, skin care management, exer-
cise potential, and associated features
would aid the understanding and man-
agement of the condition.ACKNOWLEDGMENT
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